Medipal Holdings Corporation · TSE:7459
Medipal — Q2 FY2024 Earnings Presentation
23 slides from Medipal's earnings presentation, Nov 1, 2024
Slide 1: Financial Results for the 2nd Quarter Ended Sep. 30, 2024
Financial Results for the 2nd Quarter Ended Sep. 30, 2024 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to enhance its corporate value. Nov. 1, 2024 Forward-Looking Sta
Slide 2: Key Messages
Key Messages 2027 MEDIPAL Medium-Term Vision Oroshi Growing through business portfolio Change the 卸 Forever prioritizations and collaboration with partners 〜Constant Innovation〜 Growing steadily as a whole due to well-performed wholesale business, the foundation of the Group. Adjusted Operating Prof
Slide 3: Contents
Contents １．Financial Results for the 2nd Quarter Ended Sep. 30, 2024 ２．Initiatives for the FY Ending March 31, 2025 ３．Forecast of Consolidated Results and Shareholder returns for FY Ending March 31, 2025 The MEDIPAL Group has three business segments: ・ Prescription Pharmaceutical Wholesale Business
Slide 4: Consolidated Statements of Income
Consolidated Statements of Income (\ billion) 2Q/FY2023 2Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 1,778.9 1,824.6 +45.6 +2.6% Gross Profit 121.3 126.4 +5.0 +4.2% （6.82％） （6.93％） (＋0.11pp) SG&A Expenses 100.7 99.2 -1.4 -1.5% (5.66%） （5.44％） (-0.22pp)
Slide 5: Consolidated Statements of Income [Change Factors from 2Q/FY2023]
Consolidated Statements of Income [Change Factors from 2Q/FY2023] Achieved Net Sales increase in all business segments, and increased Profits as the MEDIPAL Group. Increased operating profit even excluding the impact of business investment expenses in the same period of the previous fiscal year and
Slide 6: Prescription Pharmaceutical Wholesale Business (MEDICEO Business)
Prescription Pharmaceutical Wholesale Business (MEDICEO Business) (\ billion) 2Q/FY2023 2Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 1,140.0 1,167.6 +27.6 +2.4% 69.8 74.1 +4.2 +6.1% Gross Profit (6.13%) （6.35%) (＋0.22pp) 64.4 62.2 -2.2 -3.5% SG&A Expen
Slide 7: MEDICEO Business [Change Factors from 2Q/FY2023]
MEDICEO Business [Change Factors from 2Q/FY2023] Achieving Sales and Profits growth by securing a growth rate that exceeds the market by strengthening sales strategy through utilizing MEDIPALʼs unique functions “the two Aʼs (ALCs and ARs). ALC: Area Logistics Center, AR: Asist Representatives Amount
Slide 8: Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business)
Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business) (\ billion) 2Q/FY2023 2Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 583.4 600.4 +17.0 +2.9% 43.3 44.1 +0.8 +2.0% Gross Profit (7.43%) (7.36%) (-0.07pp) 29.5 30.2 +0
Slide 9: PALTAC Business [Change Factors from 2Q/FY2023]
PALTAC Business [Change Factors from 2Q/FY2023] Exceeded Sales and Operating Profit YoY due to the successful sales expansion measures that captured the environmental change and an improvement in the SG&A ratio. Amount YoY Change Change factors from 2Q/FY2023 • Boosted demand on outing-related produ
Slide 10: Animal Health Products and Food Processing Raw Materials Wholesale (AGRO・FOOD Business)
Animal Health Products and Food Processing Raw Materials Wholesale and Related Business (AGRO・ FOOD Business) (\ billion) 2Q/FY2023 2Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 56.7 58.6 +1.8 +3.2％ 8.2 8.1 -0.0 -0.8% Gross Profit (14.50%) (13.93%) (-0.
Slide 11: AGRO・FOOD Business [Change Factors from 2Q/FY2023]
AGRO・ FOOD Business [Change Factors from 2Q/FY2023] Achieved steady Sales growth while decreased Gross Profit due to rising costs caused by the weak yen. Strengthening investments in HRs, system, and R&D for the future growth Operating Profit Amount YoY Change Change factors from 2Q/FY2023 • Animal
Slide 12: Contents
Contents １．Financial Results for the 2nd Quarter Ended Sep. 30, 2024 ２．Initiatives for the FY Ending March 31, 2025 ３．Forecast of Consolidated Results and Shareholder returns for FY Ending March 31, 2025 Copyright © 2024 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 11
Slide 13: MEDICEO Business: Logistics Reform through MEDISKET's functions
MEDICEO Business︓ Logistics Reform through MEDISKET's functions Achieving cost reductions despite increasing volume, by reforming business practices in pharmaceutical distribution through ALC functions Number of order lines and total logistics working hours Reduction in Delivery Frequency Approx. ¥0
Slide 14: PALTAC Business: Promoting "PALTAC VISION 2027"
PALTAC Business︓ Promoting "PALTAC VISION 2027" Promoting key initiatives in line with the three-year medium-term management plan. “PALTAC VISION 2027 “ - Constructing the foundation for transformation through structural reform - 【Expanding the scope of values provided by the logistics】 Started cons
Slide 15: New Businesses: Global Development of Drugs for Ultra-Rare Diseases
New Businesses︓Global Development of Drugs for Ultra-Rare Diseases Promoting the development of JR-471 and JR-446, licensed from JCR Pharmaceuticals, for patients around the world who suffer from ultra-rare diseases for which there are no treatments. Research Preclinical trials Clinical trials Appro
Slide 16: Creating Group Synergy: The Start of the New MP Gokyo Food & Chemical
Creating Group Synergy︓The Start of the New MP Gokyo Food & Chemical Merged MP Gokyo Food & Chemical and MEDIPAL FOODS in Oct. 1, 2024. Achieving growth through combining their strengths and effective use of management resources. MP Gokyo Food & Chemical MEDIPAL FOODS 主な取扱品⽬ Strengths Strengths R&D
Slide 17: Creating Group Synergy: PreMedica Joined the MEDIPAL Group
Creating Group Synergy︓PreMedica Joined the MEDIPAL Group Acquired all shares in May 2024. Accelerating the increase in users of testing services such as Flora Scan® and LOX-index® by creating synergies with group companies In the fields of "Pharmaceuticals, Health, and Beauty“, the MEDIPAL Group pr
Slide 18: Contents
Contents １．Financial Results for the 2nd Quarter Ended Sep. 30, 2024 ２．Initiatives for the FY Ending March 31, 2025 ３．Forecast of Consolidated Results and Shareholder returns for FY Ending March 31, 2025 Copyright © 2024 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 17
Slide 19: Forecast of Consolidated Results for the FY Ending March 31, 2025
Forecast of Consolidated Results for the FY Ending March 31, 2025 Proactively implementing initiatives in line with the Medium-Term Vision and making steady progress toward achieving the FY2024 forecast announced in May 2024 （\ billion） Consolidated MEDICEO Bisiness PALTAC Business AGRO･FOOD Busines
Slide 20: FY2024 Investment and Shareholder returns
FY2024 Investment and Shareholder returns Investment Strengthening investments from a medium- to long-term in growth perspective to ensure the MEDIPAL Group's sustainable growth Capital Continuing to invest to maintain and develop a safe and Investment secure distribution system for customers Sh
Slide 21: Management Philosophy
Management Philosophy Contributing to people’s health and the advancement of society through creation of value in distribution Copyright © 2024 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 20
Slide 22: Factors behind YoY Changes in Non-Operating and Extraordinary Income/Expenses
Appendix Factors behind YoY Changes in Non-Operating Income/Expenses and Extraordinary Income/Expenses Non-Operating Income/Expenses Extraordinary Income/Expenses ¥ billion -0.75 +1.15 +4.46 -1.25 -1.94 Gain on step acquisitions -1.29 -0.11 +6.93 -1.89 +6.53 +0.04 +0.13 Compensation +0.36 +5.78 inco
Slide 23: Copyright © 2024 MEDIPAL HOLDINGS CORPORATION, All rights reserved.
Copyright © 2024 MEDIPAL HOLDINGS CORPORATION, All rights reserved.